LFCR Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -18.7% compared to Lifecore Biomedical's net margin of -49.65%. Lifecore Biomedical's return on equity of 475.5% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Lifecore Biomedical has a consensus price target of --, signalling upside risk potential of 5.26%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Lifecore Biomedical, analysts believe NovaBay Pharmaceuticals is more attractive than Lifecore Biomedical.

Lifecore Biomedical has a beta of 0.988, which suggesting that the stock is 1.212% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Lifecore Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Lifecore Biomedical quarterly revenues are $37.9M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Lifecore Biomedical's net income of -$7.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Lifecore Biomedical's price-to-earnings ratio is 152.00x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical is 2.09x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Outset Medical has a net margin of -18.7% compared to Lifecore Biomedical's net margin of -97.47%. Lifecore Biomedical's return on equity of 475.5% beat Outset Medical's return on equity of -145.43%.

Lifecore Biomedical has a consensus price target of --, signalling upside risk potential of 5.26%. On the other hand Outset Medical has an analysts' consensus of $5.79 which suggests that it could grow by 253.98%. Given that Outset Medical has higher upside potential than Lifecore Biomedical, analysts believe Outset Medical is more attractive than Lifecore Biomedical.

Lifecore Biomedical has a beta of 0.988, which suggesting that the stock is 1.212% less volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lifecore Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

Lifecore Biomedical quarterly revenues are $37.9M, which are larger than Outset Medical quarterly revenues of $28.7M. Lifecore Biomedical's net income of -$7.1M is higher than Outset Medical's net income of -$27.9M. Notably, Lifecore Biomedical's price-to-earnings ratio is 152.00x while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical is 2.09x versus 0.50x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

Precision Optics has a net margin of -18.7% compared to Lifecore Biomedical's net margin of -31.24%. Lifecore Biomedical's return on equity of 475.5% beat Precision Optics's return on equity of -34.86%.

Lifecore Biomedical has a consensus price target of --, signalling upside risk potential of 5.26%. On the other hand Precision Optics has an analysts' consensus of -- which suggests that it could fall by --. Given that Lifecore Biomedical has higher upside potential than Precision Optics, analysts believe Lifecore Biomedical is more attractive than Precision Optics.

Lifecore Biomedical has a beta of 0.988, which suggesting that the stock is 1.212% less volatile than S&P 500. In comparison Precision Optics has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.901%.

Lifecore Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical pays -- of its earnings as a dividend. Precision Optics pays out -- of its earnings as a dividend.

Lifecore Biomedical quarterly revenues are $37.9M, which are larger than Precision Optics quarterly revenues of $4.2M. Lifecore Biomedical's net income of -$7.1M is lower than Precision Optics's net income of -$1.3M. Notably, Lifecore Biomedical's price-to-earnings ratio is 152.00x while Precision Optics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical is 2.09x versus 1.64x for Precision Optics. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -18.7% compared to Lifecore Biomedical's net margin of -788.06%. Lifecore Biomedical's return on equity of 475.5% beat Sage Therapeutics's return on equity of -48.2%.

Lifecore Biomedical has a consensus price target of --, signalling upside risk potential of 5.26%. On the other hand Sage Therapeutics has an analysts' consensus of $24.39 which suggests that it could grow by 64.23%. Given that Sage Therapeutics has higher upside potential than Lifecore Biomedical, analysts believe Sage Therapeutics is more attractive than Lifecore Biomedical.

Lifecore Biomedical has a beta of 0.988, which suggesting that the stock is 1.212% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.067%.

Lifecore Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Lifecore Biomedical quarterly revenues are $37.9M, which are larger than Sage Therapeutics quarterly revenues of $11.9M. Lifecore Biomedical's net income of -$7.1M is higher than Sage Therapeutics's net income of -$93.6M. Notably, Lifecore Biomedical's price-to-earnings ratio is 152.00x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical is 2.09x versus 3.11x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.